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Abstract
The human monoclonal antibody (mAb) HK20 neutralizes a broad spectrum of primary HIV-1 isolates by targeting the highly
conserved heptad repeat 1 (HR1) of gp41, which is transiently exposed during HIV-1 entry. Here we present the crystal
structure of the HK20 Fab in complex with a gp41 mimetic 5-Helix at 2.3 A˚ resolution. HK20 employs its heavy chain CDR H2
and H3 loops to bind into a conserved hydrophobic HR1 pocket that is occupied by HR2 residues in the gp41 post fusion
conformation. Compared to the previously described HR1-specific mAb D5, HK20 approaches its epitope with a different
angle which might favor epitope access and thus contribute to its higher neutralization breadth and potency. Comparison
of the neutralization activities of HK20 IgG, Fab and scFv employing both single cycle and multiple cycle neutralization
assays revealed much higher potencies for the smaller Fab and scFv over IgG, implying that the target site is difficult to
access for complete antibodies. Nevertheless, two thirds of sera from HIV-1 infected individuals contain significant titers of
HK20-inhibiting antibodies. The breadth of neutralization of primary isolates across all clades, the higher potencies for C-
clade viruses and the targeting of a distinct site as compared to the fusion inhibitor T-20 demonstrate the potential of HK20
scFv as a therapeutic tool.
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Introduction
The HIV-1 envelope (Env) glycoprotein is the main target for
neutralizing antibodies. Thus a successful HIV-1 vaccine must
induce broadly cross-clade neutralizing antibodies as an essential
correlate of protection against infection [1]. The HIV-1 genome
and especially its env gene is highly variable between and within
clades [2], which is partly responsible for the difficulty in
developing a suitable vaccine candidate [3,4]. Consequently, the
search for conserved targets is the basis of current attempts to
develop an effective HIV-1 vaccine.
Trimeric Env is composed of the receptor binding domain
gp120, which is non-covalently associated with the membrane-
anchored fusion protein gp41. Infection of target cells is initiated
by the attachment of Env to the CD4 receptor [5,6], which
triggers conformational changes that expose the hypervariable
loop 3 (V3) [7], thus priming it for co-receptor CCR5 or CXCR4
interaction [8,9]. Together CD4 and co-receptor interactions are
thought to induce conformational changes in the fusion protein
subunit resulting in exposure and subsequent insertion of the
fusion peptide into the target cell membrane which produce the
fusion intermediate pre-hairpin structure that bridges viral and
cellular membranes [10,11]. During this process heptad repeat
regions 1 (HR1) and 2 (HR2) are transiently exposed [12]
permitting interaction with peptide inhibitors of fusion such as T-
20 [13,14]. Subsequent refolding of the pre-hairpin structure into
the post-fusion conformation [15,16,17,18] leads to the apposition
of viral and cellular membranes catalyzing membrane fusion [19].
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The fusion-intermediate conformation of gp41 is an attractive
target for neutralizing antibodies due to its relative high sequence
conservation. Broadly cross-clade neutralizing antibodies 2F5,
4E10 and Z13 target the membrane proximal region most likely
during epitope exposure in the fusion-intermediate pre-hairpin
conformation [20,21,22]. A number of monoclonal antibodies
directed against HR1 exposed in the pre-hairpin conformation of
gp41 have been isolated from phage display libraries, which show
variable neutralization profiles depending on the neutralization
assays used. MAb D5 was isolated from a naı¨ve human library
[23] and MAb DN9 from a Fab library generated from bone
marrow RNA from an HIV-1 infected individual [24], while the
rabbit single chain mAb 8K8 was derived from a phage library
[24] prepared from rabbits immunized with a gp41 HR1 mimetic
[25]. Several HR1-specific Fabs were also isolated from a human
non-immune phage library [26,27] and Fab 3674 was in vitro
matured [28]. Notably, immunization strategies employing HR1
peptide mimetics led to the generation of a polyclonal antibody
response capable of neutralizing Tier 1 primary isolates [29].
The crystal structure of the D5 Fab in complex with the gp41
mimetic 5-Helix [30] reveals that D5 binds orthogonal to the axis
of the HR1 trimer. The principal interaction site is a conserved
hydrophobic pocket on gp41 [31] that is the target for HR2
[15,16], D-peptides and various peptide mimetics [25,32,33],
demonstrating that D5 binding blocks the transition into the six-
helix conformation required for entry [31].
We previously reported the isolation of the gp41-specific
antibody HK20 from immortalized memory B cells of an HIV-1
infected individual, which targets the conserved hydrophobic
pocket in gp41 HR1 [34]. HK20 has a considerable breadth of
neutralization on isolates from multiple clades. However the
neutralizing potency was low and target cell dependent [34].
Here we present the crystal structure of the HK20 Fab in
complex with gp41 5-Helix as well as a detailed characterization of
HK20 neutralizing properties. The structure reveals that HK20
occupies a conserved hydrophobic pocket within the HR1 triple
stranded coiled coil, indicating that HK20 binding inhibits
membrane fusion by interfering with HR2 refolding into the six
helix bundle post fusion conformation. Although HK20 and D5
occupy the same site on HR1, their angle of interaction vary
substantially, which might account for the differences in
neutralization potencies. Comparison of the neutralization activ-
ities in different assays reveals a much higher potency for smaller
HK20 Fab and scFv over IgG, suggesting steric as well as temporal
constraints. HK20 scFv neutralize all pseudoviruses tested as well
as infectious viruses by targeting a conserved site that is not
affected by T-20 resistance mutations.
Results
Structure of the HK20 Fab in complex with 5-Helix
The crystal structure of HK20-5-Helix complex was solved by
molecular replacement and refined to a resolution of 2.3 A˚
(Table 1). The variable domains (VH and VL) of the Fab
approach the epitope in an ,60u angle with respect to the 5-Helix
trimer axis (Figure 1A). HK20 employs the complementarity
determining regions (CDR) H2, H3 and L3 to contact two
adjacent HR1 helices (Figure 1B). The tip of CDR H2 is a
central determinant of interaction (Figure 2A) and positions Ile53
and Phe54 into a hydrophobic HR1 pocket (lined by HR1 chain a
Leu565, Leu568, Thr569 and HR1 chain c Val570* and Ile573*)
(Figure 2B). Furthermore CDR H2 Asp55 makes a water
mediated contact to the carbonyl of Lys574 followed by a
hydrophobic contact of Ile56. CDR H3 contacts HR1 chain a.
The aromatic ring of Tyr97 is within p stacking distance to His564
and its orientation is supported by a hydrogen bond to the
Author Summary
The HIV-1 envelope glycoprotein composed of the
receptor binding subunit gp120 and the fusion protein
gp41 is the prime target for neutralizing antibodies.
Receptor binding induces a conformational change in
gp41 that transiently exposes the conserved heptad repeat
1 (HR1) region. We have previously isolated the human
HR1-specific mAb HK20 and provide now the structural
basis for epitope recognition. HK20 employs mainly its
CDR H2 and H3 for binding similar to HR1 binding of mAb
D5. We demonstrate that HK20 and D5 bind HR1 with
similar affinities; however, HK20 has a broader neutraliza-
tion breadth than D5, which might be due to the
differences in their approach angles of epitope recogni-
tion. Competition analyses of 33 sera from HIV-1 infected
individuals reveal significant titers of HK20-inhibiting
antibodies in 20 cases, confirming the immunogenicity of
the epitope. We demonstrate further that HK20 IgG have
limited neutralization breadth and potency while smaller
HK20 Fabs and scFv reveal a broad cross clade neutrali-
zation breadth. This suggests that the accessibility of the
HR1 epitope limits the value of HR1 mAbs for infection
prevention, but highlights the importance of smaller
versions such Fabs or scFv to combat infection alone or
in synergistic approaches with other antivirals.
Table 1. Data collection and refinement statistics.
Data collection
Space group P21
Cell dimensions
a, b, c (A˚), b (u) 75.95, 62.71, 76.61; 97.70u
Wavelength (A˚) 0.9765
Resolution (A˚) 45.00-2.30 (2.42 – 2.30)a
Mesured reflections 95264
Unique reflections 28254
Rmerge 0.12 (0.35)
I / sI 4.0 (2.1)
Completeness (%) 93.30 (89.20)
Redundancy 3.2 (2.4)
Wilson B factor (A˚2) 32.00
Refinement
Resolution (A˚) 37.60 - 2.30
Rcryst (Nu reflections) 0.239 (28254)
Rfree (Nu reflections) 0.279 (1509)
No. atoms
Protein 4960
Water 118
B-factors (A˚2) 35.97
R.m.s deviations
Bond lengths (A˚) 0.009
Bond angles (u) 1.183
aNumber in parentheses refer to the highest resolution shell.
doi:10.1371/journal.ppat.1001195.t001
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carbonyl of CDR H1 Arg31. The carbonyl of CDR H3 Ser99
hydrogen bonds to Trp571 NE1, whose aromatic ring forms a
hydrophobic sandwich with the ring structure of Pro100b, itself
stacked by Tyr100c (Figure 2C). Tyr100c also participates in a
network of hydrogen bonds by contacting Gln575, which makes a
double dent hydrogen bond to CDR H2 Asn58 (Figure 2D). The
binding contribution of the light chain is minor and restricted to
hydrophobic contacts by Asp93 and Leu94 to Ala578 and Ala582
of HR1 (Figure 2D). A water molecule coordinated by CDR H3
Ser98 and the carbonyl of Tyr97 contacts HR2 His 643. Docking
demonstrates that three Fabs or antibodies could bind simulta-
neously to all three epitopes once they become exposed during the
fusion reaction (Figure 3). The crystal structure reveals that the
tip of HK20 CDR H2 occupies the hydrophobic pocket on HR1
that, in the post-fusion conformation, is filled by HR2 residues
Trp626, Trp631 and Ile635 (Figure 4A) [15,16]. In addition, the
side chain of Trp571 rotates by ,90u to accommodate binding to
CDR H3 (Figures 4A, B and 2C). Thus the HK20 interaction
blocks entry by preventing the folding of HR2 onto HR1 which is
required to catalyze fusion of viral and cellular membranes in
order to establish infection [35].
Comparison of the HK20 and D5 interaction with 5-Helix
Fab D5, previously isolated from a human naive phage display
library, uses similar structural principles for interaction with HR1
[31]. Its CDR H2 tip reaches into the HR1 pocket employing
Ile53 and Phe54 for interaction (Figure 4C) with Phe54
occupying the identical position of HK20 CDR H2 Phe54
(Figure 4B). In contrast, D5 residue Gly55 replaces the important
HK20 CDR H2 residue Asp55. D5 binding is supported by a
shorter CDR H3 compared to HK20 (Figure S1 in Supporting
Information S1), whereas D5 CDR H3 Pro97 is sandwiched
between HR1 chain A residues His564 and Trp571 (Figure 4C).
Other D5 contacts are provided by CDR L3 and by two
interactions with HR2 residues, including a water mediated
contact to HR2 His643 [31] as observed in case of HK20
interaction. Although HK20 and D5 VH domains are encoded by
very similar germline genes, namely VH1-69*5 and VH1-69*1,
HK20 shows four amino acid somatic mutations in CDR H2,
while D5 uses the germline sequence of CDR H2 for interaction
(Figure S1 in Supporting Information S1). The second
important contribution of interaction comes from the CDR H3
region, which is completely different in both antibodies since it is
encoded by D6-6*01 and J3*02 gene segments (HK20) and D1-
Figure 1. HK20 Fab binds to a conserved epitope on gp41 HR1.
(A) Ribbon diagram of the HK20 Fab (heavy chain in blue and light
chain in green) approaching its epitope on gp41 (HR1 in yellow and
HR2 in grey) looking down the three-fold axis of gp41 (upper panel).
The lower panel shows the side view of the complex and shows that the
Fab complex approaches 5-Helix with an approximate angle of 60u. (B)
Close-up of the HK20 interaction with 5-Helix. The complementarity
determining regions are coloured differently and labelled H (heavy
chain) and L (light chain).
doi:10.1371/journal.ppat.1001195.g001
Figure 2. Close-up of the HK20-5-Helix interactions. (A) Only
CDR H2 (blue), H3 (green) and L3 (yellow) contact two HR1 helices of 5-
Helix. (B) Close-up of the hydrophobic and polar interactions mediated
by CDR H2. (C) Close up of CDR H3 interactions highlighting the
sandwich structure produced by residues H564, Y97, W571, P100b and
Y100c. (D) Close-up of the polar network formed by CDR H2 N58, H3
Y100c and gp41 HR1 chain A Q575.
doi:10.1371/journal.ppat.1001195.g002
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14*1 and J4*02 gene segments (D5). Both antibodies employ
different light chain gene segments (HK20 VL, V33*1 and J4*02;
D5 VL, V5*01 and J4*1).
In spite of structural differences described above, both mAbs
show a similar interaction footprint on the 5-Helix structure, with
HK20 and D5 occupying a surface of 1061 A˚2 and 1156 A˚2,
respectively (Figures 5A, B). Notably, Ca super positioning of both
complexes reveals that HK20 approaches its epitope on HR1 in a
different angle than D5. While D5 binds almost perpendicular to
the 5-Helix trimer axis [31], HK20 approaches the epitope in a
,60u angle between the 5-Helix trimer axis and the HK20 major
axis (Figure 6A). This difference in interaction is more visible when
the Ca atoms of the Fabs are super positioned, which reveals the
dramatic change in HR1 trimer axis orientation between the two
complexes (Figure 6B). The close up of the Ca super positioning
highlights the distinct and common features of interaction of CDR
H3 (Figure 6C) and H2 (Figure 6D) indicating that the same
epitope can be targeted by different approach angles.
Binding kinetics and role of somatic mutation
Surface plasmon resonance measurements showed an affinity
constant (KD) of 3.3 nM for HK20 and 3.1 nM for D5 IgG
binding to a gp41 HR1 mimetic. Both HK20 and D5 show similar
association rates of ka = 2.2060.015 10
5 M21 s21 and
ka = 3.3560.022 10
5 M21 s21 and similar dissociation rates of
kd = 7.2761.05 10
24 s21 and kd = 10.360.089 10
24 s21, respec-
tively, suggesting that the minor difference in affinity does not
explain the differences in neutralization as outlined below.
The contribution of somatic mutations was investigated by
comparing, employing a 5-Helix-based ELISA, HK20, D5 and
HK20 variants in which the VH and/or VL were reverted to the
germline configuration. HK20 and D5 showed comparable EC50
values (0.1 mg/ml), while the HK20 variants in which the heavy
chain alone or both heavy and light chains were reverted to
germline showed approximately 50-fold lower binding (EC50 6.2
and 4.8 mg/ml). In contrast the germline reversion of VL alone
had no measurable effect on binding using the ELISA assay
(Figure S2A in Supporting Information S1). These binding
results were also confirmed by the lack of neutralizing activity by
the germline HK20 version or by the HK20 variant in which the
light chain was reverted to germline when tested in parallel with
HK20 in the HOS.CD4-R5 target cell assay against clade A and
C HIV-1 isolates (Figure S2B and C in Supporting
Information S1). These results are consistent with structural
data described above and demonstrate that somatic mutations in
the light chain do not contribute significantly to binding, while
those in the heavy chain represent the positive contribution of
somatic hyper-mutations to the affinity maturation of mAb
HK20.
Detection and quantification of HK20-like antibodies in
patient sera
HK20 was an affinity selected antibody isolated from the
memory B cell repertoire of an HIV-1 infected individual. To
establish whether similar antibodies would be generally produced
in the context of the immune response to HIV-1 infection we
developed a competitive assay suitable for the detection and
quantification of HK20-like antibodies in patients’ sera. Serial
dilutions were tested for their capacity to inhibit binding of
biotinylated HK20 to immobilized 5-Helix. Twenty out of 33 sera
from HIV-1 infected individuals showed significant titers of
HK20-inhibiting antibodies, while the remaining did not show
significant inhibition, in spite of variable binding to 5-Helix
(Figure 7A and B). We conclude that the HK20-footprint is
targeted by antibodies in a significant fraction of HIV-infected
patients.
Comparison of HK20 and D5 neutralizing activity
HK20 and D5 IgG were compared for their capacity to
neutralize a panel of 18 HIV-1 Tier-1 and Tier-2 isolates spanning
6 clades. The assays were performed using either TZM-b1 or
HOS.CD4-R5 as target cells. In the TZM-b1-based assay HK20
neutralized 4 out of 18 HIV-1 isolates with IC50 values below
300 mg/ml (,2000 nM), while D5 neutralized only one Tier 1
virus (Figure 8 and Table S1 in Supporting Information
S1). In contrast in the HOS-based assay, HK20 neutralized all 18
isolates tested with IC50 values ranging from 7 to 1173 nM, while
D5 neutralized only 11 out of 18 isolates with IC50 values ranging
from 126 to 1930 nM (Figure 8 and Table S1 in Supporting
Information S1). Thus, in spite of a similar molecular
interaction with the target epitope, HK20 shows a higher potency
and breadth of neutralization as compared to D5.
Figure 3. The gp41 prehairpin structure can bind three HK20
mAbs simultaneously. Molecular model demonstrating the docking
of three HK20 Fabs onto three HR epitopes formed by three HR1 helices
(Figure 1A; a-c, c-b and a-b). Note that no molecular clashes occur upon
binding of all three Fabs. The upper panel shows the complex as
viewed down the gp41 three-fold axis and the lower panel shows the
complex in a side view indicating the orientations of the membrane
anchors. The arrows show the directions of the viral membrane and of
the fusion peptide that will be inserted into the target cell membrane.
doi:10.1371/journal.ppat.1001195.g003
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Figure 4. HK20 occupies a hydrophobic pocket on HR1, which
is filled by HR2 in the six helix bundle post fusion conforma-
tion. (A) Close-up of the six helix bundle conformation of the HK20
epitope. The HR1 trimer is shown as a molecular surface (yellow) and
the HR2 helix pointing residues Trp626, Trp631 and Ile635 into the
pocket is shown as coil motif. (B) Close up of the HK20 CDR H2 pointing
into the hydrophobic pocket together with the main structural
principles of CDR H3 and L3 interactions. (C) Close-up of the D5
interaction sites reveals similar structural principles as shown for HK20
(see B).
doi:10.1371/journal.ppat.1001195.g004
Figure 5. Surface representation of the HK20 and D5 footprints
on 5-Helix. Interface area of HK20 (A) and of D5 (B). The HR1 surface is
shown in yellow, the HR2 surface in grey and residues making direct
contacts with HR1 are marked in red and HR2 in pink. Both HK20 and
D5 interact indirectly with HR2 His643 via water-mediated hydrogen
bonds.
doi:10.1371/journal.ppat.1001195.g005
Crystal Structure of HK20 in Complex with gp41
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Size dependent neutralization activity of HK20
The HR1 region recognized by HK20 is only transiently
exposed and has limited accessibility during the membrane fusion
reaction [36] [37]. Our previous finding that HK20 Fab showed
higher potency than IgG in an HOS-based assay [34] would be
consistent with steric constraint in the accessibility of this epitope.
We therefore tested whether further reducing the size of HK20 to
single chain Fv (scFv) would increase neutralizing activity in the
most demanding TZM-bl assay. HK20 IgG, Fab and scFv were
compared in a TZM-b1-based assay against a panel of 45 Tier 1, 2
and 3 HIV-1 pseudoviruses (Figure 9A and Table S2 in
Supporting Information S1). The HK20 Fab showed high
breadth and potency, since it neutralized 43 out of the 45 viruses
with IC50 values ranging from 14 to 1000 nM (Figure 9A and
Table S2 in Supporting Information S1). HK20 scFv showed
on average a 2–6 times higher potency as compared to the Fab
Figure 6. Ca super positioning of the HK20-5-Helix and the D5-
5-Helix complexes reveals differences in epitope approach
angles. (A) Ca super positioning of the 5-Helix HR1 helices A and C
reveals differences in the approach angles of both complexes. While D5
binds in an orthogonal way to its HR1 epitope, HK20 approaches the
epitope in an ,60u angle. (B) The difference in binding angle is also
supported by the Ca super positioning of VH and HR1 chains a and c.
(C) Close-up of the super positioning of HK20 and D5 CDR H3 loops
demonstrating their differences in interaction with the HR1 helix. (D)
Close-up of the super positioning of HK20 and D5 CDR H2 loops
highlights the central role of Phe54 contacting two HR1 helices.
doi:10.1371/journal.ppat.1001195.g006
Figure 7. Detection of HK20-like antibodies in patient sera. (A)
ELISA plates were coated with 5-Helix and incubated with serial plasma
dilutions, followed by biotinylated HK20 mAb and by enzyme-
conjugated streptavidin. Shown is the reciprocal plasma dilution that
blocks 80% binding (BD80) of HK20 mAb. BD80 values ,20 (empty
circles) were scored as negative. Each symbol represents a different
individual. (B) Total serum IgG binding to 5-Helix was determined by
ELISA. Reciprocal EC50 values are shown. Empty circles correspond to
plasma samples with BD80 values ,20.
doi:10.1371/journal.ppat.1001195.g007
Figure 8. Comparison of HK20 IgG and D5 IgG in TZM-bl and
HOS-based neutralization assays. HK20 (circles) and D5 (squares)
were tested for their capacity to neutralize the same 18 HIV-1
pseudoviruses representing 6 different clades in TZM-bl and HOS-cell
based assays. Shown are nM IC50 values, (empty circles or squares, IC50
.2000 nM (.300 mg/ml).
doi:10.1371/journal.ppat.1001195.g008
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and neutralized all 45 pseudoviruses with IC50 values ranging
from 6 to 737 nM (Figure 9A and Table S2 in Supporting
Information S1). Interestingly, HK20 scFv neutralized clade C
isolates more potently than clade B viruses. This observation was
further supported by testing HK20 scFv against a larger panel of
clade B and C isolates (27 and 25 isolates, respectively, p= 0.0023)
(Figure 9B and Table S3 in Supporting Information S1).
We then compared HK20 scFv with the T-20 peptide (Fuzeon)
in both HOS and TZM-bl based assays using a panel of 20 isolates
(Figure 9C and Table S4 in Supporting Information S1).
HK20 scFv neutralized the same HIV-1 isolates with IC50 values
10–100 fold lower in HOS cells as compared to TZM-b1 cells
(IC50 values ranging from 0.8 to 174 nM and 43 to 430 nM,
respectively). T-20 neutralization was also more efficient in the
HOS cells as compared to TZM-bl cells, with IC50 values ranging
from ,2.23 to 20 nM and 0.04 to 4.4 nM in TZM-bl and HOS
assays, respectively. The breadth of HIV-1 neutralization by
HK20 scFv is very high considering the high number of isolates
tested and compares favorably with the reference broadly
neutralizing mAbs b12 (27 out of 45), 2G12 (12 out of 45), 2F5
(22 out of 45), 4E10 (44 out of 45) and 447-52D (6 out of 45)
(Table S5 in Supporting Information S1).
Given the limitations inherent to pseudoviruses and cell lines we
compared HK20-scFv, T-20 and TriMab (a cocktail of the
broadly neutralizing mAbs 2F5, 2G12 and b12) in a PBMC-based
neutralization assays using nine primary replication-competent
HIV-1 isolates representative of clades A, B, C, D and E
(Figure 9D and Table S6 in Supporting Information S1).
HK20 scFv neutralized 8 out of the 9 isolates tested with IC90
values ranging from 95 to 1667 nM. Interestingly, the two HIV-1
isolates neutralized more potently (i.e. Du174 and 92BR025) were
clade C viruses.
In conclusion these results demonstrate that reduction of size
dramatically increased HK20 scFv breadth and potency of viral
neutralization in different assays, including PBMC-based assays.
Discussion
In this study we present the crystal structure of the HR1-specific
human mAb HK20 in complex with 5-Helix. HK20 binds to the
same region recognized by the previously described mAb D5 [31],
but differs significantly in the contact sites, in the angle of
approach and shows a role for somatic mutations in affinity
maturation. These aspects influence both potency and breadth of
neutralization, which are higher for HK20 compared to D5 and
depend on somatically mutated residues. In addition, we show that
in case of HK20 the scFv is at least 15-fold more potent in
neutralization than IgG, consistent with a limited accessibility to
the target site.
The gp41 footprints of HK20 and D5 and the global structural
principles employed by both antibodies are similar. CDR H2 and
H3 loops contribute the main interactions in both cases whereas
Phe 54 at the tip of CDR H2 points into a hydrophobic pocket
that is occupied by gp41 HR2 residues in the post fusion
conformation [15,16,31]. Notably, the same germline V gene
family encodes the VH regions of HK20 and D5. While CDR2
H2 from D5 did not carry somatic mutations, HK20 CDR H2 is
mutated and contains four amino acid changes which are required
for high affinity binding. CDR H3 from HK20 and D5 follow
distinct structural principles to contact the HR1 epitope, consistent
with their different D and J gene usage. While HK20 CDR H2
contacts two HR1 helices, its CDR H3 contacts only one HR1
helix. In contrast, CDR H3 from D5 contacts two HR1 helices. As
far as light chains are concerned, D5 uses all three light chain
CDRs to interact with HR1 and HR2 and D5 CDR L3 contacts
are important since mutation of CDR L3 Y94A leads to the loss of
neutralization [31]. In contrast HK20 does not bind directly to
HR2 and HK20 CDR L3 contributes only two hydrophobic
contacts (Leu 94 and Asp 93). The minor role of the HK20 light
chain is further underlined by our data showing that the light
chain can be replaced by the germline sequence without loss of
binding activity. In conclusion, HK20 employs primarily two
CDR loops to contact gp41, while D5 utilizes all six CDRs, which
might indicate that the interaction with gp41 is less rigid for HK20
as compared to D5. This might permit HK20 to engage with a
higher degree of conformational flexibility, as suggested by normal
mode analyses, which permit to study the vibrational and thermal
properties of the complex [38]. Interestingly, the crystal structure
reveals that HK20 and D5 Fabs approach the same HR1 epitope
with different angles; while D5 binds almost orthogonal towards
HR1, HK20 contacts 5-Helix in a ,60u angle. It is conceivable
that these different approaches may influence the accessibility to
the target site.
Previous studies reported variable effects of size on viral
neutralization by HR1 targeting molecules. For instance, the size
of fusion proteins coupled to T-20 affected neutralization
efficiency [36], while fusions to C34 had no effect [37]. D5 IgG
and scFv showed comparable or slightly higher potency IC50
values [23,39]. In contrast, HK20 Fab and scFv showed, on a
Figure 9. Size dependent neutralization breadth and potency
of HK20 in different HIV-1 neutralization assays and compar-
ison with T-20. (A) Neutralization of 45 HIV-1 isolates in TZM-bl cells
by HK20 IgG (empty circles), Fab (red circles) and scFv (black circles).
Shown are nM IC50 values. (B) Neutralization of 27 clade B and 25 clade
C HIV-1 isolates in TZM-bl cells by HK20 scFv. Shown are nM IC50 values.
Two-tailed P value was calculated with the unpaired t test. (C) HK20
scFv (black circles) and T-20 (empty triangles) were tested for their
capacity to neutralize 20 HIV-1 isolates using either TZM-bl (left panel)
or HOS (right panel) as target cells. Shown are nM IC50 values. The
dotted line indicates the lowest concentration tested. (D) HK20 scFv
(black circles), TriMab (2F5, 2G12 and b12, empty squares) and T-20
(empty triangles) were tested in a PBMC-based neutralization assay
against a panel of 9 HIV-1 primary isolates from 5 different clades.
Shown are nM IC90 values. The dotted lines indicate the highest
concentration tested. Virus isolates used and detailed results are shown
in Tables S1, S2, S3, S4, S5 in Supporting Information S1.
doi:10.1371/journal.ppat.1001195.g009
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molar basis, at least 15-fold higher potency as compared to the
corresponding IgG. The fact that HK20 Fab and scFv efficiently
neutralize all pseudoviruses tested indicates that the HR1 epitope
is easily accessible for proteins of 50 kDa or less and that in the
intact IgG the presence of the Fc and/or the second Fab arm
obstructs epitope access. It is also possible that temporal
constraints during the fusion reaction play an important role in
explaining the lower activity of IgG over Fab/scFv, since the
diffusion rate of IgG (4.961027 cm2/sec) is slightly slower than
that of Fab (7.461027 cm2/sec) [40].
Both D5 and HK20 show similar kinetics of binding. Our SPR
measurements indicated a Kd of 3.1 nM for D5, higher than the
previously reported values of 0.26 nM [23] and 0.05 nM [31],
which, however, have been obtained with 5-Helix as analyte and
thus include contributions of HR2 binding. Thus the small
differences in affinity are not necessarily the best correlate of viral
neutralization, corroborating that neutralization is most likely
critically dependent on accessibility to the HR1 target epitope and
possibly other factors.
The conformational states of gp41 have been studied extensively
and are attractive targets for fusion inhibitors and neutralizing
antibodies due to the sequence conservation of gp41
[1,13,14,32,41,42]. However, it is not clear whether this conserved
site is sufficiently immunogenic to trigger a neutralizing antibody
response in vivo. In addition, since HR1 is only transiently exposed
during the fusion reaction, it is itself an unfavorable target for
induction of a B cell response. On the other hand, since many Env
complexes found on virions are non-functional, it is possible that
the prolonged exposure of the HK20 epitope on such complexes
induces HK20-like antibodies and favors their affinity maturation.
Unlike D5, which was isolated from a phage library, HK20 was
isolated from a memory B cell of an HIV-1 infected individual and
was therefore selected in vivo in the course of HIV-1 infection.
When reverted to the germline sequence HK20 still bound to the
5-Helix with 50-fold lower affinity but did not show neutralizing
activity, indicating a critical role for somatic mutations to achieve
high affinity binding and neutralization. Shuffling of Ig chains
showed that mutations in the heavy but not in the light chain
contributed to the increased binding affinity, a finding that is
consistent with the structural data, which reveal only a minor role
of CDR L3 for HR1 recognition.
In this study we used HK20 as a probe to quantify serum
antibodies directed against the same site. Using an HK20 blocking
assay we found that some HIV-1 infected individuals (20 out of 33)
have variable levels of HK20-like antibodies with titers ranging
from 1:21 to 1:528, which might include neutralizing and non-
neutralizing antibodies. A recent study demonstrated that
constructs containing HR1 and HR2 can be used to isolate by
affinity chromatography from human immune sera antibodies
with neutralizing activity in a PBMC-based assay [43]. However it
remains to be determined which is the fraction of HR1-reactive
antibodies endowed with neutralizing activity [24].
Different neutralization assays employing different target cells
produce differences in neutralization breadth and potency with the
result that no single assay is capable of detecting the entire
spectrum of neutralizing activities [44]. Our findings demonstrate
that antibodies that target HR1 are particularly sensitive to the
target cell used. Indeed for both HK20 and D5 IgG we found
much higher neutralization titers in the HOS-based as compared
to the TZM-b1-based assay. It is possible that the high level of
CD4 and CCR5 expression on TZM-b1 cells facilitates faster
membrane fusion or might even cause a rapid internalization of
the virus in the endosomal compartment thus limiting the time
window available for antibodies to bind [45,46]. It is also worth
noting that HK20 potency is generally higher against clade C as
compared to clade B viruses, which might be due to differences in
the kinetics of virus entry.
The HR1 epitope recognized by HK20 is highly conserved
(Figure S3 in Supporting Information S1) and only two
positions tolerate amino acid exchanges. Notably, the JR-FL
isolate has an Arg at position 564 rather than His or Gln which are
found in .99.5% of the isolates and is only poorly neutralized by
HK20 (IC50 174 nM on HOS cells). A similar finding was
reported for mAb 8K8 [24]. Our HK20-gp41 structure demon-
strates that His 564 is important to coordinate CDR H3 HR1
interaction, which can explain the poor neutralization of JR-FL.
T-20 is a peptide inhibitor that targets the gp41 fusion
machinery [14]. HK20 scFv shows a neutralization breadth
comparable to that of T-20 but on average a ,3.4 fold lower
potency on a molar basis in the HOS-based assay. Interestingly,
the HK20 epitope does not overlap with the T-20 binding site and
consequently we predict that HK20 will be able to neutralize T-20
escape mutants affecting the 547-GIV-549 region [47,48]. Thus
HK20 scFv represents a new tool to combat HIV-1 infection in
general and specifically T-20-resistant viruses. Furthermore HK20
scFv or HK20 scFv mimetics might demonstrate an improved
serum half life when compared to T-20 [49] or the next generation
of peptide fusion inhibitors [50]. In addition, HK20 may synergize
with HR2-specific antibodies or with small molecule entry
inhibitors, as reported for mAb D5 in combination with mAb
2F5 [51].
Although HR1 is an attractive target for antibodies due to its
high sequence conservation, an open question remains whether
HK20-like antibodies are useful in the prevention of infection.
While initial studies suggested that this might be a difficult goal
[24], a recent study suggested that immunization with HR1
mimetics can induce relevant titers of HR-1 specific neutralizing
antibodies in a species-dependent fashion [29].
In summary our structural and functional data illustrate the
general principle that the conserved fusion machinery of gp41 can
be targeted by antibodies produced in the course of HIV-1
infection. However, as demonstrated by HK20, the neutralizing
activity may be severely limited by the accessibility of the epitope
and by the size of the antibody. We propose that HK20 scFv,
smaller engineered single domain HK20 versions or HK20
mimetics with oral bioavailability represent novel tools, comple-
mentary to T-20, to combat HIV-1 infection.
Materials and Methods
Protein expression and purification
The cDNA corresponding to 5-Helix [30] was synthesized
(Geneart) and cloned into vector pETM-13 (EMBL, Heidelberg)
and 5-Helix was expressed in E. coli strain BL21gold (DE3)
(Invitrogen). Cells were grown to an OD600nm of 0.7 and induced
with 1 mM IPTG at 37uC. After 5 hours cells were harvested by
centrifugation and lysed in buffer A (0.02 M Tris pH 8.0, 0.1 M
NaCl). The soluble fraction was discarded and the pellet was
resupended in buffer A supplemented with 0.2% octyl-b-D-
glucopyranoside (Sigma) over night at 4uC. Solubilised proteins
were separated on an anionic exchange column employing a
gradient of buffer A and B (0.02 M Tris pH 8.0, 0.5 mM NaCl).
Further purification was carried out by gel filtration on a Superdex
200 column (GE Healthcare) in buffer A. Gp41-HR1 is a modified
version of a circular permutated gp41 where the C-helix precedes
the N-helix in sequence and HR2 is truncated to expose the HR1
epitope [52]. Gp41-HR1 is fused N-terminally to a 30 amino acid
triple stranded coil (pIQI) [53] to increase solubility. Gp41-HR1
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was cloned into pETM11 and expressed in E. coli strain BL21gold
(DE3) (Invitrogen). Cells were grown to an OD600nm of 0.7 and
induced with 1 mM IPTG at 37uC. After 3 hours cells were
harvested by centrifugation and lysed in buffer A and purified on a
Ni2+-NTA column. A final purification step included gel filtration
on a S75 Superdex column in buffer A.
HK20 IgG was proteolysed for 4h at 37uC with immobilized
papain (Roche) in buffer C (0.05 M Bis-Tris pH 6.3). Reaction
was stopped with E-64 and filtering the solution through a 0.22um
filter (Millipore). Proteolysed HK20 was dialyzed overnight at 4uC
in buffer D (0.025 M sodium acetate pH 5.0) and Fab fragments
were separated from Fc fragments by cationic exchange
chromatography in buffer D. Further purification was achieved
by passing the Fabs over a mono P chromatofocusing column (GE
Healthcare) and a final step included gel filtration on a Superdex
200 column (GE Healthcare) in buffer A. HK20 Fabs were mixed
with 5-Helix using a 0.5 M excess of HK20 Fabs. The complex
was separated on a Superdex 75 column in buffer A and complex
formation was confirmed by separation of the complex on a 12%
SDS-Tris-Tricine gel and on a 10% native PAGE.
Crystallisation, data collection and structure
determination
HK20-5-Helix complex crystals were obtained by the vapour
diffusion method in hanging drops mixing equal volumes of
complex and reservoir solution (0.1 M Hepes pH 7.5, 0.2 M
Ammonium sulphate, 25% PEG 3350 (w/v)). Crystal quality was
improved and single crystals were obtained by microseeding of
crystals into drops equilibrated with reservoir buffer (0.1 M Hepes
pH 7.5, 0.2 M Ammonium sulphate, 21% PEG 3350 (w/v)).
The crystal was cryo-cooled at 100 K in reservoir buffer
containing 25% (v/v) glycerol. A complete dataset was collected at
the ESRF (Grenoble, France) microfocus beamline ID23-2. Data
were processed and scaled with MOSFLM [54], and SCALA
[55,56]. The crystals belong to space group P21 with unit cell
dimensions of a = 75.95A˚, b = 62.71A˚, c = 76.61 and b=97.70u.
The structure was solved by molecular replacement using
PHASER [57] and the D5-5-Helix complex structure as a search
model (pdb ID 2CMR). The position of 5-Helix was first localized
and the positions of heavy and light chains were successively
determined. An initial model was build with ARP/WARP [58]
and completed by several cycles of manual model building with
COOT [59] and refinement with REFMAC [60] using data to
2.3 A˚ resolution (Table 1). The final model contains 5-Helix HR1
residues 543–584 (chain A), 541–581 (chain B), 543–582 (chain C)
and HR2 residues 626–664 (chain D), 624–664 (chain E). The
linker regions connecting HR1 and HR2 are disordered. HK20
residues include H chain residues 3–216 and L chain residues 1–
214. Molecular graphics figures were generated with PyMOL (W.
Delano; http://www.pymol.org). Co-ordinates and structure
factures have been deposited in the Protein Data Bank with
accession ID 2xra.
Surface plasmon resonance
BIAcore measurements were performed with the Biacore X
instrument (BIAcore. Inc.) at 25uC in running buffer (10 mM Tris
pH 8.0, 100 mM NaCl, 0.005% surfactant P20, 50 mM NiCl).
Ni2+ NTA chips were coated with gp41-HR1 to a target of 2000
response units (RU). The analyte mAbs D5 and HK20 (dialyzed
o/n in running buffer) was passed over the chip surface at
concentrations ranging from 1 nM to 50 nM for 160 seconds at a
flow rate of 20 ml/min and dissociation was recorded during
5 minutes. The chip was regenerated with 20 ml of 35 mM EDTA
at 50 ml/min. Binding kinetics were evaluated using the BiaEva-
luation software package (BIAcore, Inc.) using a Langmuir model
1:1 with no mass transfer.
Viruses and mAbs
The clade B and C HIV-1 reference panels of Env clones [61]
[62] and the SF162 clone were obtained from the NIH-AIDS
Research and Reference Reagent Program (ARRRP). Other non-
clade B isolates were provided by the Comprehensive Antibody
Vaccine Immune Monitoring Consortium (CA-VIMC). HIV-1
subtype B clone JRFL was kindly provided by Dennis Burton
(Scripps Institute, La Jolla, US). Pseudoviruses were produced by
co-transfecting HEK293T/17 cells with the env expressing
plasmids and the complementing viral-genome reporter gene
vector, pNL4-3.Luc+.E2R+ (kindly provided by John R. Mascola,
VRC, NIAID, NIH, US). TriMab was kindly provided by CFAR,
NIBSC-HPA, UK. Virus supernatants Du174, CM244,
92UG024, RW9209, QH0692, VI191, 92BR025 and MN(P)
were part of the NeutNet Virus Panel and distributed through the
Programme EVA Centre for AIDS Reagents (CFAR) NIBSC-
HPA, UK [44], and J213, a subtype B X4 virus is part of a
pediatric virus isolation panel [63].
Neutralization assays
TZM-b1 and HOS.CD4-R5 cells were obtained from the NIH
AIDS Research and Reference Reagent program (ARRRP). A
single cell infectivity assay was used to measure the neutralization
of luciferase-encoding viruses pseudotyped with the HIV-1 Env
proteins [64]. Both the HOS-CD4-R5 cell based assay and the
TZM-b1 cell based assay were performed as described [34].
PBMC-based virus titration and neutralization assay
Virus titrations (ID50) were performed in a PHA-activated
PBMC culture, as previously described [65]. For the neutralization
assay 10 to 50 Tissue Culture ID50 (TCID50) of virus were used,
though a virus titration was always performed simultaneously with
the neutralization assay to calculate the precise TCID50 of each
test run. Each reagent was tested in duplicate, in 4 steps of 4-fold
dilutions, against two 2-fold dilutions of virus. The protocol is
available on the EUROPRISE website www.europrise.org, with a
slight modification: cells were washed at day 3 by exchanging the
culture supernatant with fresh culture medium. The culture
supernatant was harvested at day 7 and tested with an in house HIV
p24 antigen ELISA (Aalto Bio Reagents, Ireland).
Analysis of antibody sequences and design of germline-
like antibodies
The heavy and light chain nucleotide sequences were analyzed
using the IMGT database. Germline-like sequences were deter-
mined by reverting mutations to the germline sequence while
retaining the original CDR3 junctions and terminal deoxy-
nucleotidyl transferase (TdT) N nucleotides.
Gene synthesis and expression plasmid constructions
IgG and scFv DNAs corresponding to mature and germline-like
HK20 and D5 heavy and light nucleotide sequences were
synthesized by Genescript (Genescript, Piscatawy, NJ) and their
accuracies were confirmed by sequencing. D5 VH and VK
sequences were obtained through the Protein Data Bank (PDB
accession code 2CMR). The scFv HK20 was designed to encode
the VK gene followed by a (GGGGS) linker, the VH gene and a
C-terminal His-tag. AgeI and HindIII restriction sites were added
to 59 and 39 termini, respectively, during gene synthesis for cloning
into the appropriate expression vectors. IgG1 expression vectors
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contained human IgG1 or Igk constant regions (kindly provided
by Michel Nussenzweig, Rockefeller University, New York, US).
The His-tag was used subsequently for scFv purification.
Recombinant antibody production and purification
Monoclonal antibodies were produced by transient transfection
of suspension cultured 293 freestyle cells with PEI. Supernatants
from transfected cells were collected after 7 days of culture.
Recombinant IgG or scFv were affinity purified with Protein A or
Ni2+ chromatography (GE Healthcare), respectively, according to
the manufacturer’s instructions, and finally desalted against PBS
using a HiTrap FastDesalting column.
Competition assay to detect HK20-like antibodies in
patient sera
HK20 mAb was biotinylated using the EZ-Link NHS-PEO
solid-phase biotinylation kit (Pierce). The competition between
polyclonal serum antibodies and biotinylated mAb for binding to
immobilized 5-Helix was measured by ELISA. Briefly, plasma
samples were added to 5-Helix-coated plates at different dilutions.
After 1 hour, biotinylated mAb was added at a concentration
corresponding to 80% of the maximal OD level, and the mixture
was incubated at room temperature for 1 hour. Plates were then
washed and bound biotinylated mAb was detected using AP-
labeled streptavidin (Jackson Immunoresearch). The percentage of
inhibition was tested in duplicates and calculated as follows:
(12[(OD sample2OD neg ctr)/ (OD pos ctr2OD neg ctr)])6100.
BD80 value was calculated by interpolation of curves fitted with a
4-parameter nonlinear regression.
Sequence sources
The accession code of the env sequence of 5-Helix corresponds
to the gp41 sequence of HXB2 (AAA76685; 5-Helix, 2CMR). The
D5 heavy chain sequence (CH and VH) are deposited under
2CMR and the D5 light chain (CL and VL) under 2CMR in the
NCBI protein database and SwissProt. The sequences of the
HK20 heavy and light chains have been deposited with PDB ID
code 2xar.
Supporting Information
Supporting Information S1 Supplementary figures and tables
Found at: doi:10.1371/journal.ppat.1001195.s001 (2.22 MB PDF)
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